Therefore, the present study examined the different effects of one-week oral administration of aripiprazole on the Akt-GSK3β and Dvl-GSK3β-β-catenin signalling pathways in three schizophrenia-related brain regions in comparison with a D2R antagonist—haloperidol and a D2R partial agonist—bifeprunox. This evidence concerns the gene DRD2 and schizophrenia.